A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing.
Benderski K, Schneider P, Kordeves P, Fichter M, Schunke J, De Lorenzi F, Durak F, Schrörs B, Akilli Ö, Kiessling F, Bros M, Diken M, Grabbe S, Schattenberg JM, Lammers T, Sofias AM, Kaps L.
Benderski K, et al. Among authors: schneider p.
Pharmacol Res. 2024 Dec 25;211:107560. doi: 10.1016/j.phrs.2024.107560. Online ahead of print.
Pharmacol Res. 2024.
PMID: 39730106
Free article.